Hodgkin Lymphoma Consortium: Pooling epidemiologic data for a research resource

霍奇金淋巴瘤联盟:汇集流行病学数据作为研究资源

基本信息

项目摘要

DESCRIPTION (provided by applicant): For Hodgkin lymphoma (HL), a common cancer of children and young adults, epidemiologic research has identified some risk factors, but the most important finding has been significant heterogeneity across patient and tumor characteristics (e.g., age, histologic subtype, tumor cell Epstein-Barr virus). Thus, the etiology of HL remains unclear, and in large part this is because its low incidence limits study sample sizes, particularly for the stratified analyses required addressing this heterogeneity. For the ultimate aim of primary prevention, additional studies of HL risk factors therefore are needed, but they must be very large. With the very efficient approach of combining existing HL epidemiologic data resources for collaborative re-analyses, we propose to form a consortium of HL studies within the NCI Inter Lymph consortium, pool data from these studies, and use the pooled dataset initially to test two novel hypotheses not addressable in individual studies. The study aims are to: 1) obtain and summarize descriptive information (data dictionaries, questionnaires, lists of data resources), and core demographic and tumor data for future analysis planning, from all participating HL studies; 2) post summarized study information and pooled core data frequencies on the Inter Lymph internet portal for reference for planning future analysis; 3) in the pooled dataset, test whether: a) ultraviolet light exposure is inversely related to HL risk; and b) HL cases with and without a family history of HL or lymphoma have differing risk factors suggesting environmental modification of genetic susceptibility. Leaders of 22 international HL studies have agreed to pool their resources (interview data, tumor specimens, and/or DNA on ~16,000 HL cases and 37,000 controls), following well-established and successful Inter Lymph policies and procedures. The pooled resource will be among the largest databases for study HL etiology ever compiled. Study strengths include: 1) producing a very powerful database for evaluating novel and extant risk factors within and across etiologically relevant subcategories of HL, for a level of insight about HL causes and outcomes not heretofore possible; 2) extremely efficient use of existing resources, with a large information gain for a relatively small cost; 3) efficient use of existing infrastructure in a successful international consortium of epidemiologic studies; 4) initial analyses in the pooled data in two promising areas: ultraviolet light exposure, a novel HL risk factor that is modifiable; and environmental modification of the well-described familial HL, with implications for etiology and clinical management of high-risk families.
描述(申请人提供):霍奇金淋巴瘤(HL)是一种常见的儿童和年轻人癌症,流行病学研究已经确定了一些危险因素,但最重要的发现是患者和肿瘤特征(如年龄、组织亚型、肿瘤细胞爱泼斯坦-巴尔病毒)之间存在显著的异质性。因此,HL的病因仍不清楚,这在很大程度上是因为它的低发病率限制了研究样本量,特别是对于解决这种异质性所需的分层分析。为了达到初级预防的最终目的,因此需要对HL危险因素进行额外的研究,但这些研究的规模必须非常大。通过结合现有的HL流行病学数据资源进行协作性再分析的非常有效的方法,我们建议在NCI国际淋巴联盟内形成一个HL研究联盟,汇集这些研究的数据,并最初使用汇集的数据集来测试两个在个别研究中无法解决的新假设。这项研究的目的是:1)从所有参与的HL研究中获取和总结描述性信息(数据词典、问卷、数据资源列表),以及用于未来分析规划的核心人口和肿瘤数据;2)发布总结研究信息,并在国际淋巴门户网站上汇集核心数据频率,以供未来分析参考;3)在汇集的数据集中,测试:a)紫外线暴露是否与HL风险呈负相关;以及b)有或无HL或淋巴瘤家族史的HL病例具有不同的风险因素,提示环境因素改变了遗传易感性。22项国际HL研究的带头人已经同意按照完善和成功的国际淋巴政策和程序,汇集他们的资源(采访数据、肿瘤标本和/或约16,000例HL病例和37,000例对照的DNA)。汇集的资源将是有史以来汇编的研究HL病因学的最大数据库之一。研究优势包括:1)创建一个非常强大的数据库,用于评估HL病因学相关亚类内和跨病因学相关亚类的新的和现有的风险因素,从而深入了解HL的病因和结果;2)非常有效地利用现有资源,以相对较小的成本获得大量信息;3)在成功的国际流行病学研究联盟中有效利用现有的基础设施;4)在两个有希望的领域对汇集的数据进行初步分析:紫外线暴露,一种可改变的新的HL风险因素;以及对描述良好的家族性HL进行环境改造,对高危家庭的病因学和临床治疗产生影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ellen Ting-Yee Chang其他文献

Ellen Ting-Yee Chang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ellen Ting-Yee Chang', 18)}}的其他基金

Groundwork for a study of non-smoking-associated lung cancer in AsianPacific Isla
亚太岛屿非吸烟相关肺癌研究的基础
  • 批准号:
    7792203
  • 财政年份:
    2009
  • 资助金额:
    $ 7.25万
  • 项目类别:
Vitamin D, alcohol, and risk of lymphomas in a prospective cohort of women
前瞻性女性队列中的维生素 D、酒精和淋巴瘤风险
  • 批准号:
    7659998
  • 财政年份:
    2009
  • 资助金额:
    $ 7.25万
  • 项目类别:
Groundwork for a study of non-smoking-associated lung cancer in AsianPacific Isla
亚太岛屿非吸烟相关肺癌研究的基础
  • 批准号:
    7659995
  • 财政年份:
    2009
  • 资助金额:
    $ 7.25万
  • 项目类别:
Vitamin D, alcohol, and risk of lymphomas in a prospective cohort of women
前瞻性女性队列中的维生素 D、酒精和淋巴瘤风险
  • 批准号:
    7769913
  • 财政年份:
    2009
  • 资助金额:
    $ 7.25万
  • 项目类别:
Hodgkin Lymphoma Consortium: Pooling epidemiologic data for a research resource
霍奇金淋巴瘤联盟:汇集流行病学数据作为研究资源
  • 批准号:
    7688486
  • 财政年份:
    2008
  • 资助金额:
    $ 7.25万
  • 项目类别:
Aspirin use, genetic variation in aspirin related-genes, and Hodgkin lymphoma ris
阿司匹林的使用、阿司匹林相关基因的遗传变异和霍奇金淋巴瘤
  • 批准号:
    7320144
  • 财政年份:
    2007
  • 资助金额:
    $ 7.25万
  • 项目类别:
Determinants of the secular increase in NHL
NHL 长期增加的决定因素
  • 批准号:
    6908767
  • 财政年份:
    2004
  • 资助金额:
    $ 7.25万
  • 项目类别:
Diet and Risk of Ovarian Cancer
饮食与卵巢癌的风险
  • 批准号:
    6952387
  • 财政年份:
    2004
  • 资助金额:
    $ 7.25万
  • 项目类别:
Determinants of the secular increase in NHL
NHL 长期增加的决定因素
  • 批准号:
    6741144
  • 财政年份:
    2004
  • 资助金额:
    $ 7.25万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 7.25万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.25万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 7.25万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.25万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 7.25万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.25万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 7.25万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 7.25万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 7.25万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 7.25万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了